In this article, we will discuss Lapatinib Ditosylate (Dosage Overview). So, let’s get started.
Lapatinib Ditosylate is indicated in combination with:
• capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
• letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib Ditosylate in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
HER2 Positive Metastatic Breast Cancer: The recommended dose of Lapatinib Ditosylate is 1,250 mg given orally once daily on Days 1-21 continuously in combination with capecitabine
2,000 mg/m²/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. Lapatinib Ditosylate should be taken at least one hour before or one hour after a meal. The dose of Lapatinib Ditosylate should be once daily (5 tablets administered all at once); dividing the daily dose is not recommended. Capecitabine should be taken with food or within 30 minutes after food. If a day’s dose is missed, the patient should not double the dose the next day. Treatment should be continued until disease progression or
unacceptable toxicity occurs. Hormone Receptor Positive, HER2 Positive Metastatic Breast Cancer: The
recommended dose of Lapatinib Ditosylate is 1,500 mg given orally once daily continuously in combination with letrozole. When coadministered with Lapatinib Ditosylate, the recommended dose of letrozole is 2.5 mg once daily. Lapatinib Ditosylate should be taken at least one hour before or one hour after a meal. The dose of Lapatinib Ditosylate should be once daily (6 tablets administered all at once); dividing the daily dose is not recommended.